![]() Medical marijuana products are currently distributed by dispensaries in the U.S and, in some countries, by pharmacies. In keeping with the regulations of a given state or country, medical marijuana can be consumed via inhalation, orally (alone or incorporated into edible food items), topically for designated medical conditions and in suppository form. There are additionally over 100 phytocannabinoids and many other largely uncharacterized compounds in cannabis with the exact composition varying, depending on growing conditions, plant variety, and method of manufacturing/formulation 4–8. CBD does not have psychoactive properties, but can have actions on the brain 1–3. THC is the psychoactive component (the “high”) of the cannabis plant. The plants of Cannabis genus contain a large number of chemical compounds called phytocannabinoids, of which delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most abundant. Medical marijuana is composed of the dried leaves, flowers, stems and seeds from the Cannabis genus plants, usually made from strains of Cannabis sativa or Cannabis Indica. Medical marijuana, also often called medical cannabis, refers to the use of marijuana obtained from an approved source and recommended by a healthcare provider to treat a medical condition. Read the Tourette Association of America’s Position Statement What is medical marijuana? ![]() There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders. The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana.There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies. A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports.Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS: The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. To maintain transparency to the public and to ensure the reporting of accurate information, MAPS has released the results of the five rounds of secondary analytical testing of the chemical composition of NIDA cannabis (see below).The Cannabis Consortium Review of the Literature Executive Summary Prior to initiating enrollment in the study, laboratory testing of the NIDA cannabis was conducted over five months. MAPS is testing the safety and efficacy of four different potencies of smoked NIDA cannabis to manage symptoms of chronic, treatment-resistant post-traumatic stress disorder (PTSD) in 76 veterans in a placebo-controlled clinical trial. ![]() MAPS is committed to sponsoring rigorous clinical research to develop cannabis into a prescription medicine through the Food and Drug Administration (FDA). As of March 15, 2017, five participants have received marijuana (cannabis) provided by the National Institute on Drug Abuse (NIDA) in an ongoing Phase 2 clinical trial sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) at the Scottsdale Research Institute (SRI) in Phoenix, Ariz.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |